Key result
Deferoxamine administered before primary percutaneous coronary intervention for STEMI did not significantly reduce CMRI-determined infarct size compared with placebo (17.4% vs 18.6%; P=0.73).
Why the study?
Does deferoxamine administered before primary PCI reduce myocardial infarct size and oxidative stress in patients with ST-elevation-MI?
Population
60 patients with ST-elevation-myocardial infarction undergoing primary percutaneous coronary intervention
Comparison
Deferoxamine intravenous bolus immediately… vs Normal saline bolus and infusion (placebo)
Design
RCT, randomly assigned
Follow-up
3 months (100±17 days)
Authors
Loading...
Does not support deferoxamine before primary PCI to limit STEMI infarct size; challenges iron chelation for acute cardioprotection.
RCT (n=60)
Does deferoxamine administered before primary PCI reduce myocardial infarct size and oxidative stress in patients with ST-elevation-MI?
Absolute Event Rate: 17.4% vs 18.6%
p-value: p=0.73
Adjunctive intravenous deferoxamine administered before primary PCI in STEMI patients reduces oxidative stress but does not reduce myocardial infarct size.
Chan et al. (2012) conducted an RCT in ST-elevation-myocardial infarction (n=60). Deferoxamine vs. Placebo (normal saline) was evaluated on CMRI-determined infarct size at day 3±1 (p=0.73). Deferoxamine administered before primary percutaneous coronary intervention for STEMI did not significantly reduce CMRI-determined infarct size compared with placebo (17.4% vs 18.6%; P=0.73).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: